Today: 19 May 2026
CapitaLand Investment share price: What 9CI holders watch after director filings, ahead of Feb 11 results
1 February 2026
1 min read

CapitaLand Investment share price: What 9CI holders watch after director filings, ahead of Feb 11 results

Singapore, Feb 1, 2026, 15:06 SGT — Market closed.

  • CapitaLand Investment (SGX:9CI) ended the day unchanged, closing at S$3.08.
  • Filings late in the week revealed shifts in director interests related to treasury share transfers.
  • CapitaLand Ascott Trust, a major managed trust, released its FY2025 distribution figures as earnings season kicks off.

CapitaLand Investment shares (SGX:9CI) closed flat on Friday at S$3.08, fluctuating within a range of S$3.05 to S$3.10. The stock traded roughly 13 million shares.

As the Singapore market remains closed for the weekend, attention turns to the upcoming wave of full-year results and distribution announcements from CapitaLand-managed listed vehicles, followed by the manager’s own earnings. This stretch could shift expectations around fee income and capital recycling, even if the parent company’s stock stays muted.

Friday brought a wave of board-related disclosures. On their own, these filings rarely shift a stock, but they can stir up some noise when liquidity is light.

David Su Tuong Sing disclosed buying 25,009 shares on Jan. 28 at S$2.543 each, acquiring them through a transfer of treasury shares. This raised his direct stake from 55,241 to 80,250 shares. Treasury shares refer to stock a company holds post-buyback and can be allocated for share-based payments without issuing fresh shares.

CapitaLand Ascott Trust, managed by subsidiaries of CapitaLand Investment, reported on Thursday. The trust held its full-year distribution per stapled security (DPS) steady at 6.10 Singapore cents, even as income available for distribution climbed 11% to S$256.7 million. Serena Teo noted, “We are progressing towards our medium-term portfolio allocation of 25%–30% in the living sector.” Lui Chong Chee added, “Looking ahead, we are focused on delivering sustainable growth and long-term value for our Stapled Securityholders.” The trust confirmed that stapled securityholders will receive their second-half payout on Feb. 27. SGX Links

CapitaLand Investment outlined a busy schedule of earnings announcements in a Singapore Exchange notice, with results from its listed funds rolling out before its FY2025 report on Feb. 11, ahead of market open. The lineup starts with CapitaLand India Trust on Feb. 2, followed by CapitaLand China Trust and CapitaLand Ascendas REIT on Feb. 5, and then CapitaLand Integrated Commercial Trust on Feb. 6.

The filing noted that CapitaLand Investment plans a results briefing at 9 a.m. on the day it reports earnings, open to invited analysts and media. There will be a “live” webcast available. SGX Links

CapitaLand Investment manages real assets and collects fees from overseeing listed property trusts and private funds. Morningstar reports its total assets under management stood at SGD 117 billion as of June 30, 2025.

The downside risk is straightforward. If upcoming results reveal weaker asset values, sluggish asset sales, or faltering performance in key portfolios, fee forecasts could quickly be revised downward — and real estate managers often react sharply to that.

Next up, all eyes will be on Monday’s CapitaLand India Trust figures, followed by CapitaLand Investment’s FY2025 results scheduled for Feb. 11.

Stock Market Today

  • Indian Investors Prop Up Markets as Foreign Funds Exit Amid Global Uncertainty
    May 19, 2026, 8:03 AM EDT. The managing director of the Bombay Stock Exchange (BSE), Sundararaman Ramamurthy, attributed the avoidance of a market 'freefall' in India to strong domestic investor participation. Despite the BSE Sensex falling 11% year-to-date and being one of Asia's worst performers, Indian investors pumped a net $91 billion into equities last year, offsetting a $35 billion withdrawal by foreign investors. The reversal in foreign versus domestic holdings reflects cautious foreign sentiment, dampened by weak earnings, rising oil prices linked to Middle East conflict, and India's lack of major AI companies compared with other Asian markets. Domestic equity mutual fund inflows surged 58% in April to nearly $4 billion, signaling robust local confidence amid global challenges.

Latest articles

MetaVia Stock Moves Ahead of the Open After Obesity-Drug Data Picked for ADA

MetaVia Stock Moves Ahead of the Open After Obesity-Drug Data Picked for ADA

19 May 2026
Diploma PLC shares rose 4.75% to 6,940p after the company raised its 2026 outlook, citing strong demand and a 17% rise in first-half revenue to £851.1 million. Adjusted operating profit climbed 33% to £208.9 million, and the interim dividend increased 5% to 19.1p. The Controls division posted 26% organic growth. Diploma completed 15 acquisitions worth about £310 million in the past year.
Zeta Global Pops Again as Traders Eye OpenAI Ad Deal

Zeta Global Pops Again as Traders Eye OpenAI Ad Deal

19 May 2026
Zeta Global shares rose 3.4% to $19.85 in premarket trading Tuesday after CEO David Steinberg announced an advertising agreement with OpenAI at a JPMorgan conference. The stock had closed up 11.6% at $19.19 on Monday, trading over 17 million shares. Bank of America reinstated coverage with a Buy rating and $24 target. Zeta recently reported first-quarter revenue up 50% year-over-year to $396 million.
Home Depot Earnings Show Housing Stress for Wall Street

Home Depot Earnings Show Housing Stress for Wall Street

19 May 2026
Home Depot reported first-quarter sales of $41.8 billion, up 4.8%, beating estimates, but comparable sales rose just 0.6%, missing analyst forecasts. Net earnings fell to $3.3 billion from $3.4 billion a year earlier. The company kept its 2026 outlook unchanged. Shares edged higher in premarket trading.

Popular

Regeneron stock sinks after cancer trial miss prompts selloff

Regeneron stock sinks after cancer trial miss prompts selloff

19 May 2026
Regeneron Pharmaceuticals shares fell 9.8% to $629.68 Monday after its late-stage melanoma drug trial with fianlimab failed to meet the main goal. The study did not show a statistically significant benefit over Merck’s Keytruda. At least 10 brokerages cut price targets. The decline outpaced broader market losses, with the Nasdaq down 0.5%.
Renesas stock price: Wolfspeed stake update lands days before Feb. 5 earnings
Previous Story

Renesas stock price: Wolfspeed stake update lands days before Feb. 5 earnings

Saks Off 5th liquidation sales begin as Saks Global moves to close 57 stores
Next Story

Saks Off 5th liquidation sales begin as Saks Global moves to close 57 stores

Go toTop